Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/10/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Andrew P. Mazar PhD

Wrong Dr. Andrew P. Mazar PhD?

Chief Scientific Officer

Local Address: San Diego, California, United States
Tactic Pharma LLC
1007 Church St., Suite 307
Evanston , Illinois 60201
United States

Company Description: Tactic Pharma is a biopharmaceutical company developing pre-clinical and clinical stage compounds for unmet medical needs. Tactic currently has four compounds under...   more
Background

Employment History

Education

  • PhD
  • Ph.D. , Biochemistry
    University of Illinois College of Medicine
29 Total References
Web References
Management
www.tacticpharma.com, 10 July 2014 [cached]
Andrew P. Mazar, PhD Chief Scientific Officer
Dr. Mazar is recognized internationally for his work on the urokinase plasminogen activator (uPA) system and its role in tumor progression. In addition to his research work on the uPA system, Dr. Mazar is a veteran of drug discovery having led various oncology drugs from basic research through phase II clinical trials.
Prior to Tactic Pharmaceuticals, Dr. Mazar was Chief Scientific Officer at Attenuon, where he led the development of three drug projects from discovery into human clinical trials. He was also the Vice President of Biology at Ångstrom Pharmaceuticals, Inc., where he discovered the anti-angiogenic peptide Å6, which is currently being evaluated in phase II trials in oncology. He also discovered a novel uPA receptor-targeting peptide Å17, which was licensed to Diatide/Schering AG. Prior to Ångstrom, Dr. Mazar spent over seven years at Abbott Laboratories, where he initiated two anti-angiogenesis pilot projects and was involved in the pre-clinicaldevelopment of two biologic agents that went through Phase III trials.
Dr. Mazar is also the co-inventor on twelve issued patents, forty pending patent applications, ninety-six full publications in refereed scientific journals, and eight book chapters including reviews on the uPA system, mouse tumor models and the therapeutic targeting of cancer. Dr. Mazar received his Ph.D. in Biochemistry from the University of Illinois College of Medicine.
International Protease Network - People
www.protease.net, 19 Oct 2013 [cached]
Professor Andrew P. Mazar, Ph. D. Chief Scientific Officer, Senior Vice President, Research and Development Attenuon, L.L.C., 10130 Sorrento Valley Rd Suite B, San Diego, CA 92121
Attenuon
www.attenuon.com, 7 Aug 2010 [cached]
Andrew P. Mazar, Ph.D. Chief Scientific Officer
Home > Andrew Mazar, Ph. ...
www.lungtx.com [cached]
Home > Andrew Mazar, Ph. D.
...
Andrew Mazar, Ph. D.
...
Andrew Mazar, Ph. D.
Founder and Head of Product Development
Dr. Mazar serves as Head of Product Development in addition to his current position as Director of the Center for Developmental Therapeutics and Entrepreneur-in-Residence at Northwestern University. Prior to this, Dr. Mazar was most recently the Chief Scientific Officer at Attenuon, LLC and has led three projects at Attenuon through IND and into phase II trials. He is currently managing an additional three projects at various stages of IND enabling development. Prior to Attenuon, Dr. Mazar had significant input in three projects that led two successful INDs, two of which made it through phase II trials and one of which is currently in phase II trials. One of these projects was the original development of scuPA for the treatment of myocardial infarction. Thus, Dr. Mazar has extensive expertise in translating early stage science into clinical projects through phase II clinical development and managing this entire process. He also has direct experience in the development of LTI-01 (scuPA) as a clinical therapeutic agent.
During his tenure in biotechnology, Dr. Mazar has led several projects that culminated in several out-license deals as well as funded collaborations. A new partnership deal with a large European venture group on all of Attenuon's projects has closed. During the partnership process, Dr. Mazar led early and late stage discussion with most every large and mid-size biotechnology company interested in cancer therapeutics. During these discussions, terms sheets were obtained from five different suitors, all of them public companies. While at Attenuon, Dr. Mazar managed $63M of investment capital, the majority of this raised through a single investor, during his nine year tenure and led a road show managed by Bank of America.
Attenuon
www.attenuon.com, 7 Aug 2010 [cached]
Andrew P. Mazar, Ph.D. Attenuon
...
Andrew P. Mazar, Ph.D. - Chief Scientific Officer
Dr. Mazar received his Ph.D. in Biochemistry from the University of Illinois College of Medicine. He is a veteran of drug discovery and development efforts and is internationally recognized for his basic research work on the role of the urokinase plasminogen activator (uPA) system in tumor progression and angiogenesis. At Attenuon, he has led the development of two drugs through phase II trials in cancer and a third drug into pre-clinical development. Previously, Dr. Mazar established and directed all facets of pre-clinical research for Ångstrom Pharmaceuticals, Inc., where he was Vice President, Biology. He is the inventor of both the anti-angiogenic peptide Å6, currently being evaluated in phase II trials in oncology, and a novel uPA receptor-targeting peptide that was licensed to Diatide/Schering AG. Prior to Ångstrom, Dr. Mazar spent over seven years at Abbott Laboratories, where he initiated two anti-angiogenesis pilot projects and was involved in the pre-clinical development of two biologic agents that went through Phase III trials. Dr. Mazar has been a Co-Chair for the subcommittee on Tumor Metastasis, Invasion, and Progression for the American Association for Cancer Research Annual Meeting and a member of the scientific organizing committee for the 2006 International Society for Fibrinolysis and Proteolysis and is a frequent member of NIH study sections. He is also the co-inventor on eight issued patents, thirty one pending patent applications, sixty nine full publications in refereed scientific journals and four book chapters including reviews on the uPA system, mouse tumor models and the therapeutic targeting of integrins.
Other People with the name "Mazar":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304